Ticagrelor versus clopidogrel in patients with chronic coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis
In this cohort of patients with CCS undergoing PCI, ticagrelor was associated with a lower incidence of MACE at 1-year follow-up compared to clopidogrel, without an increase in major bleeding. Dedicated randomised controlled trials are needed to confirm these findings.
Authors
- Manuel Jesús Romero-Jiménez (ORCID: https://orcid.org/0000-0003-2794-9710)
- F. Costa
- Jorge L Perea
- M Ling Pan
- Ignacio Gallo (ORCID: https://orcid.org/0009-0000-1593-4760)
- Javier Suárez de Lezo (ORCID: https://orcid.org/0000-0002-8285-3693)
- Luis Carlos Maestre
- Gloria Heredia
- Francisco Hidalgo
- Cristina Urbano
- Soledad Ojeda
- Diana Ladera
- Rafael Gonzalez-Manzanares
- Inmaculada Osuna
Institutions
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Instituto de Investigación Biomédica de Málaga (ES)
- University of Córdoba (ES)
- Universidad de Málaga (ES)
Publication Details
- Journal
- Medicina Clínica
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1016/j.medcli.2025.107256
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00